Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.7 |
mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |